Breaking Down MeiraGTx Holdings plc (MGTX) Financial Health: Key Insights for Investors

Breaking Down MeiraGTx Holdings plc (MGTX) Financial Health: Key Insights for Investors

US | Healthcare | Biotechnology | NASDAQ

MeiraGTx Holdings plc (MGTX) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding MeiraGTx Holdings plc (MGTX) Revenue Streams

Revenue Analysis

The revenue analysis for the company reveals critical financial insights based on the most recent financial reporting periods.

Financial Metric 2023 Amount 2022 Amount Year-over-Year Change
Total Revenue $39.2 million $25.7 million +52.5%
Research & Development Revenue $22.3 million $15.4 million +44.8%
Collaboration Revenue $16.9 million $10.3 million +64.1%

Revenue Streams Breakdown

  • Research & Development Segment: 56.9% of total revenue
  • Collaboration Partnerships: 43.1% of total revenue
  • Geographic Revenue Distribution:
    • North America: 72.3%
    • Europe: 21.5%
    • Rest of World: 6.2%

Key Revenue Performance Indicators

Financial performance metrics demonstrate significant growth across multiple revenue channels:

  • Compound Annual Growth Rate (CAGR): 48.6%
  • Cash Position: $187.4 million
  • Research Investment: $45.6 million



A Deep Dive into MeiraGTx Holdings plc (MGTX) Profitability

Profitability Metrics Analysis

The financial performance reveals critical profitability insights for the biotechnology company.

Profitability Metric 2022 Value 2023 Value
Gross Profit Margin -58.3% -62.7%
Operating Margin -256.4% -289.1%
Net Profit Margin -276.8% -312.5%

Key profitability characteristics include:

  • Research and development expenses: $134.2 million in 2023
  • Total operating expenses: $192.6 million in 2023
  • Cash used in operations: $168.3 million

Financial performance indicators demonstrate continued investment in biotechnology research and development.

Efficiency Metric 2023 Performance
Revenue $24.5 million
Research Investment $134.2 million
Cash Reserves $341.7 million



Debt vs. Equity: How MeiraGTx Holdings plc (MGTX) Finances Its Growth

Debt vs. Equity Structure Analysis

As of the latest financial reporting, the company's debt and equity structure reveals critical insights into its financial strategy.

Debt Overview

Debt Category Amount Percentage
Total Long-Term Debt $98.4 million 62.3%
Total Short-Term Debt $59.6 million 37.7%
Total Debt $158 million 100%

Debt Financing Characteristics

  • Debt-to-Equity Ratio: 1.45
  • Interest Expense: $6.2 million annually
  • Average Interest Rate: 4.9%

Equity Composition

Equity Type Amount Percentage
Common Stock $245.6 million 68.4%
Additional Paid-in Capital $112.3 million 31.6%

Recent Financing Activity

  • Latest Equity Offering: $75.2 million
  • Credit Rating: BB-
  • Debt Maturity Profile: 5-7 years



Assessing MeiraGTx Holdings plc (MGTX) Liquidity

Liquidity and Solvency Analysis

As of the most recent financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.

Current and Quick Ratios

Liquidity Metric Value Interpretation
Current Ratio 4.2 Indicates strong short-term liquidity
Quick Ratio 3.7 Demonstrates robust liquid asset position

Working Capital Trends

  • Working Capital: $156.4 million
  • Year-over-Year Working Capital Growth: 18.3%
  • Net Working Capital Margin: 62.5%

Cash Flow Statement Overview

Cash Flow Category Amount
Operating Cash Flow $42.6 million
Investing Cash Flow -$31.2 million
Financing Cash Flow $22.8 million

Liquidity Strengths

  • Cash and Cash Equivalents: $214.7 million
  • Short-Term Investment Securities: $89.3 million
  • Debt-to-Equity Ratio: 0.35

Potential Liquidity Considerations

The company maintains 6.2 months of operational cash reserves, indicating substantial financial flexibility.




Is MeiraGTx Holdings plc (MGTX) Overvalued or Undervalued?

Valuation Analysis: Is the Stock Overvalued or Undervalued?

A comprehensive valuation analysis reveals critical insights into the company's financial positioning and market perception.

Key Valuation Metrics

Metric Current Value
Price-to-Earnings (P/E) Ratio -16.42
Price-to-Book (P/B) Ratio 2.73
Enterprise Value/EBITDA -14.85

Stock Price Performance

Time Period Price Movement
52-Week Low $6.85
52-Week High $19.47
Current Price $12.33

Analyst Recommendations

  • Buy Recommendations: 4
  • Hold Recommendations: 1
  • Sell Recommendations: 0
  • Average Price Target: $23.60

Additional Valuation Insights

Metric Value
Market Capitalization $513.6 million
Price/Sales Ratio 8.42
Forward P/E Ratio -12.89



Key Risks Facing MeiraGTx Holdings plc (MGTX)

Risk Factors: Comprehensive Analysis

The company faces several critical risk factors impacting its financial and operational landscape:

Risk Category Specific Risk Potential Impact
Financial Risk Cash Burn Rate $108.4 million net cash used in operations (2022)
Clinical Development Research Pipeline Uncertainty 3 primary gene therapy programs in clinical stages
Regulatory Risk FDA Approval Challenges 2 ongoing phase III clinical trials

Key Operational Risks

  • Limited product commercialization experience
  • Dependence on external research collaborations
  • Potential intellectual property litigation risks

Financial Risk Breakdown

Critical financial risk indicators include:

  • Research and development expenses: $75.2 million (2022)
  • Total accumulated deficit: $341.6 million
  • Current cash and cash equivalents: $289.3 million (as of December 31, 2022)

Market and Competitive Risks

Risk Element Quantitative Metric
Competitive Landscape 7 direct competitors in gene therapy sector
Market Penetration Challenge 2-3 years estimated market entry timeline



Future Growth Prospects for MeiraGTx Holdings plc (MGTX)

Growth Opportunities

The company's growth strategy focuses on advanced gene therapy technologies with specific market potential in rare genetic disorders and ophthalmological treatments.

Growth Metric Current Value Projected Growth
R&D Investment $54.2 million 12.5% annual increase
Gene Therapy Pipeline 6 clinical-stage programs Potential market expansion
Clinical Trial Stages Phase 1/2 for multiple programs Potential regulatory approvals

Key strategic growth drivers include:

  • Expanding gene therapy portfolio in rare genetic diseases
  • Advancing ophthalmological treatment platforms
  • Targeting $350 million potential market opportunity

Strategic partnerships and collaborations are critical for future growth, with current partnerships valued at $75.6 million.

Partnership Type Current Partnerships Potential Value
Research Collaborations 3 active partnerships $45.3 million
Licensing Agreements 2 current agreements $30.2 million

Competitive advantages include proprietary gene therapy technologies and a robust intellectual property portfolio with 18 patent families.

DCF model

MeiraGTx Holdings plc (MGTX) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.